Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: A retrospective study


Aksu T., GÜLER T. E., ÇOLAK A., Baysal E., Durukan M., ŞEN T., ...Daha Fazla

BMC Cardiovascular Disorders, cilt.15, sa.1, 2015 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1186/s12872-015-0004-6
  • Dergi Adı: BMC Cardiovascular Disorders
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: No-reflow, Epinephrine, Myocardial infarction
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Despite the advances in medical and interventional treatment modalities, some patients develop epicardial coronary artery reperfusion but not myocardial reperfusion after primary percutaneous coronary intervention (PCI), known as no-reflow. The goal of this study was to evaluate the safety and efficacy of intracoronary epinephrine in reversing refractory no-reflow during primary PCI. Methods: A total of 248 consecutive STEMI patients who had undergone primary PCI were retrospectively evaluated. Among those, 12 patients which received intracoronary epinephrine to treat a refractory no-reflow phenomenon were evaluated. Refractory no-reflow was defined as persistent TIMI flow grade (TFG) ≤2 despite intracoronary administration of at least one other pharmacologic intervention. TFG, TIMI frame count (TFC), and TIMI myocardial perfusion grade (TMPG) were recorded before and after intracoronary epinephrine administration. Results: A mean of 333±123 mcg of intracoronary epinephrine was administered. No-reflow was successfully reversed with complete restoration of TIMI 3 flow in 9 of 12 patients (75%). TFG improved from 1.33±0.49 prior to epinephrine to 2.66±0.65 after the treatment (p<0.001). There was an improvement in coronary flow of at least one TFG in 11 (93%) patients, two TFG in 5 (42%) cases. TFC decreased from 56±10 at the time of no-reflow to 19±11 (p<0.001). A reduction of TMPG from 0.83±0.71 to 2.58±0.66 was detected after epinephrine bolus (p<0.001). Epinephrine administration was well tolerated without serious adverse hemodynamic or chronotropic effects. Intracoronary epinephrine resulted in significant but tolerable increase in heart rate (68±13 to 95±16 beats/min; p<0.001) and systolic blood pressure (94±18 to 140±20; p<0.001). Hypotension associated with no-reflow developed in 5 (42%) patients. During the procedure, intra-aortic balloon pump counterpulsation was required in two (17%) patients, transvenous pacing in 2 (17%) cases, and both intra-aortic balloon counterpulsation and transvenous pacing in one (8%) patients. One patient (8%) died despite all therapeutic measures. Conclusion: Intracoronary epinephrine may become an effective alternative in patients suffering refractory no-reflow following primary PCI.